{"id":11603,"date":"2024-06-28T02:19:45","date_gmt":"2024-06-28T02:19:45","guid":{"rendered":"https:\/\/economicherald.net\/?p=11603"},"modified":"2024-06-28T02:19:45","modified_gmt":"2024-06-28T02:19:45","slug":"asx-health-stocks-microba-completes-autoimmune-disease-discovery-program-with-nyse-listed-ginkgo","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=11603","title":{"rendered":"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo"},"content":{"rendered":"<p>Microba completes program with\u00a0 Ginkgo Bioworks<br \/>\nRecce reports encouraging results from Phase I\/II clinical trial<br \/>\nImricor completes second iCMR ablation procedure in Croatia<\/p>\n<p>\u00a0<\/p>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/microba-life-sciences-map\/\">Microba Life Sciences (ASX:MAP)<\/a><\/strong> has announced the successful completion of its autoimmune disease therapeutic discovery program in collaboration with <strong>Ginkgo Bioworks (NYSE: DNA)<\/strong>.<\/p>\n<p>This groundbreaking initiative was completed on schedule and within budget, with primary and secondary activity screening data received for all lead bacterial strains.<\/p>\n<p>From the comprehensive dataset generated, the program identified six strains exhibiting compelling disease-relevant activity, a significant achievement in microbiome-based therapies.<\/p>\n<p>In mid 2022, Microba and Ginkgo Bioworks embarked on a therapeutic program aimed at discovering new treatments for autoimmune diseases like lupus, psoriatic arthritis, and autoimmune liver diseases.<\/p>\n<p>Leveraging Microba\u2019s extensive databank and advanced machine learning, approximately 200 diverse gut microbiome bacterial species were identified as potential therapeutic candidates.<\/p>\n<p>Ginkgo Bioworks subsequently conducted screenings to assess these candidates for their immunomodulatory effects using a co-designed bioanalytical assay screening cascade.<\/p>\n<p>Professor Trent Munro, SVP Therapeutics at Microba, emphasised on the pioneering nature of the project, which explored novel microbes sourced from the human gut microbiome.<\/p>\n<p>\u201cMicroba is at the forefront of developing precision microbiome therapeutics, enabled by machine learning and artificial intelligence, that have the potential to help patients in need across a number of disease indications,\u201d Munro said.<\/p>\n<p>Autoimmune diseases are a family of more than 80 chronic and often life-threatening illnesses, which occur when the body\u2019s own immune system attacks the body\u2019s healthy cells, tissues and organs.<\/p>\n<p>Autoimmune conditions now impact around 5% of the population and their prevalence is rising.<\/p>\n<p>There is a growing body of evidence that the gut microbiome plays a central role in the maintenance of health and the development of this chronic disease.<\/p>\n<p>\u201cAutoimmune diseases represent a significant unmet need, and the identification of potential live biotherapeutics is an exciting development in the creation of new modalities to improve the lives of these patients,\u201d said Munro.<\/p>\n<p>\u00a0<\/p>\n<h2>Recce announces positive Phase I\/II trial results<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/recce-pharmaceuticals-rce\/\">Recce Pharmaceuticals (ASX:RCE)<\/a><\/strong> has reported encouraging results from its Phase I\/II clinical trial evaluating RECCE 327 (R327) for treating urinary tract infections (UTIs) and urosepsis.<\/p>\n<p>The trial, involving 25 participants, tested R327 at doses up to 4,000mg administered intravenously over various infusion times.<\/p>\n<p>Key findings include:<\/p>\n<p>The highest tested dose of 4,000mg of R327 demonstrated efficacy in reducing bacterial growth, specifically targeting Escherichia coli (E. coli).<\/p>\n<p>No serious adverse events were reported, and there were no clinically significant changes in laboratory results, underscoring the safety profile of R327.<\/p>\n<p>The study concluded successfully, establishing an optimal dosing regimen with a 20-minute infusion period proving most effective. This regimen showed rapid onset and sustained impact on E. coli through an ATP mechanism in participants\u2019 urine.<\/p>\n<p>Recce is now preparing to advance to a Phase II trial for UTIs, slated to commence in the second half of 2024.<\/p>\n<p>The company said these findings mark a significant step forward in its development of synthetic anti-infectives, highlighting R327\u2019s potential as a novel treatment for serious bacterial infections like UTIs and urosepsis.<\/p>\n<p>\u00a0<\/p>\n<h2>Imricor completes second iCMR Ablation in Croatia<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/imricor-medical-systems-imr\/\">Imricor Medical Systems (ASX:IMR)<\/a><\/strong> has successfully completed its second iCMR-guided atrial flutter ablation procedure at the <strong>Dubrava University Hospital<\/strong> in Zagreb, Croatia.<\/p>\n<p>This follows the hospital\u2019s recent commencement of these procedures last week, marking a rapid integration of Imricor\u2019s innovative technology.<\/p>\n<p>Dubrava University Hospital, known for its high-volume atrial flutter treatments, has already scheduled more patients for upcoming weeks, which shows the growing interest and adoption of Imricor\u2019s iCMR-guided ablations at the site.<\/p>\n<p>To support this increasing demand, Dubrava has placed an order for ten additional Vision-MR Ablation Catheter kits.<\/p>\n<p>Steve Wedan, Chair and CEO of Imricor, explained the company\u2019s strategic goals of expanding its market presence and ensuring steady procedure volumes at each activated site.<\/p>\n<p>\u201cOur sales goals this year are focused on activating more sites each quarter, and ensuring consistent procedure volume at each active site. This is how we start to establish a new standard of care.\u201d<\/p>\n<p>Wedan adds that the activation process involves several steps, starting with the purchase and installation of our iCMR EP lab equipment, which generates capital revenue for Imricor.<\/p>\n<p>\u201cAs consistent procedures follow, so does Imricor\u2019s recurring consumable revenue, which is now building momentum across the business in line with our stated objective in Q1.<\/p>\n<p>\u201cToday is the latest example of our sales team fulfilling their goals and successfully launching our groundbreaking technology across Europe,\u201d Wedan said.<\/p>\n<p>\u00a0<\/p>\n\n<p>\u00a0<\/p>\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p><em>At Stockhead we tell it like it is. While Imricor Medical Systems is a Stockhead advertiser, it did not sponsor this article.<\/em><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-microba-completes-autoimmune-disease-discovery-program-with-nyse-listed-ginkgo\/\">ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Microba completes program with\u00a0 Ginkgo Bioworks Recce reports encouraging results from Phase I\/II clinical trial Imricor completes second iCMR ablation procedure in Croatia \u00a0 Microba <a href=\"https:\/\/economicherald.net\/?p=11603\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":11604,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-11603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=11603\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Microba completes program with\u00a0 Ginkgo Bioworks Recce reports encouraging results from Phase I\/II clinical trial Imricor completes second iCMR ablation procedure in Croatia \u00a0 Microba [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=11603\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-28T02:19:45+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo\",\"datePublished\":\"2024-06-28T02:19:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603\"},\"wordCount\":796,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Microba-successfully-completed-its-autoimmune-disease-therapeutic-discovery-program-in-collaboration-with-Ginkgo-Bioworks.-Picture-Getty-RQwXDL.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=11603\",\"name\":\"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Microba-successfully-completed-its-autoimmune-disease-therapeutic-discovery-program-in-collaboration-with-Ginkgo-Bioworks.-Picture-Getty-RQwXDL.jpeg\",\"datePublished\":\"2024-06-28T02:19:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=11603\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Microba-successfully-completed-its-autoimmune-disease-therapeutic-discovery-program-in-collaboration-with-Ginkgo-Bioworks.-Picture-Getty-RQwXDL.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/Microba-successfully-completed-its-autoimmune-disease-therapeutic-discovery-program-in-collaboration-with-Ginkgo-Bioworks.-Picture-Getty-RQwXDL.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=11603#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=11603","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo - Economic Herald","og_description":"Microba completes program with\u00a0 Ginkgo Bioworks Recce reports encouraging results from Phase I\/II clinical trial Imricor completes second iCMR ablation procedure in Croatia \u00a0 Microba [more...]","og_url":"https:\/\/economicherald.net\/?p=11603","og_site_name":"Economic Herald","article_published_time":"2024-06-28T02:19:45+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=11603#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=11603"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo","datePublished":"2024-06-28T02:19:45+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=11603"},"wordCount":796,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=11603#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Microba-successfully-completed-its-autoimmune-disease-therapeutic-discovery-program-in-collaboration-with-Ginkgo-Bioworks.-Picture-Getty-RQwXDL.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=11603","url":"https:\/\/economicherald.net\/?p=11603","name":"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=11603#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=11603#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Microba-successfully-completed-its-autoimmune-disease-therapeutic-discovery-program-in-collaboration-with-Ginkgo-Bioworks.-Picture-Getty-RQwXDL.jpeg","datePublished":"2024-06-28T02:19:45+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=11603#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=11603"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=11603#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Microba-successfully-completed-its-autoimmune-disease-therapeutic-discovery-program-in-collaboration-with-Ginkgo-Bioworks.-Picture-Getty-RQwXDL.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/06\/Microba-successfully-completed-its-autoimmune-disease-therapeutic-discovery-program-in-collaboration-with-Ginkgo-Bioworks.-Picture-Getty-RQwXDL.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=11603#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Microba completes autoimmune disease discovery program with NYSE-listed Ginkgo"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/11603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11603"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/11603\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/11604"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}